89Zr-ABT806

89Zr-ABT806 is an investigational radiopharmaceutical developed as a molecular imaging agent for Positron Emission Tomography (PET). It consists of the humanized monoclonal antibody **ABT-806** (also known as depatuxizumab) conjugated to the positron-emitting radioisotope **Zirconium-89 (^89Zr)**. ABT-806 is specifically designed to target the epidermal growth factor receptor variant III (**EGFRvIII**) and the activated or overexpressed conformation of wild-type **EGFR**, which are commonly found in high-grade gliomas and other solid tumors. Unlike first-generation EGFR antibodies, ABT-806 binds to a cryptic epitope that is exposed only in the mutated or abnormally activated receptor, minimizing binding to wild-type EGFR in healthy tissues. This high selectivity allows 89Zr-ABT806 to serve as a non-invasive tool for evaluating EGFR status, assessing tumor heterogeneity, and identifying patients most likely to benefit from EGFR-targeted therapies such as antibody-drug conjugates.

Other names

89Zr-depatuxizumabdepatuxizumab [89Zr]Zirconium (89Zr) ABT-80689Zr-labeled ABT-806